deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02225405

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection

Sponsor: M.D. Anderson Cancer Center

Conditions Stage IB Non-Small Cell Lung Carcinoma AJCC v7 Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions Cisplatin Docetaxel Laboratory Biomarker Analysis Nintedanib
Updated 17 times since 2017 Last updated: May 7, 2024 Started: Apr 3, 2015 Primary completion: May 6, 2024 Completion: May 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02225405, this PHASE1 trial focuses on Stage IB Non-Small Cell Lung Carcinoma AJCC v7 and Stage II Non-Small Cell Lung Cancer AJCC v7 and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 17 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2020 · 14 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Sep 2023 · 18 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jan 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown Status → Active Not Recruiting

  3. Jan 2022 — Mar 2022 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  4. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Nov 2018 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  10. Aug 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  11. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations